Aurobindo Pharma Ltd (AUROPHARMA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aurobindo Pharma Ltd (AUROPHARMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3314
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceutical company which develops, manufactures and exports formulations and active pharmaceutical ingredients (API’s). Its products portfolio includes active pharma ingredients, formulations, antibiotics, anti-retrovirals, anti- allergics, gastroenterologicals, anti-Diabetics, HIVs, peptides, nutraceutical and aurozymes. It also offers contract research and manufacturing services across all the clinical stages of drug lifecycle. Aurobindo Pharma conducts research and development in the areas of product identification, literature evaluation, API process development, formulation development, pilot BA or BE, exhibiting batches for dossier submission, stability studies for global requirements, and dossier submission. The company has presence in China, South Africa, Australia, Germany, Japan, the US, the UK, and others. Aurobindo pharma is headquartered in Hyderabad, Telangana, India.

Aurobindo Pharma Ltd (AUROPHARMA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aurobindo Pharma to Acquire Generics Business of Apotex 13
Novartis May Sell US Generic Pill Business 14
Aurobindo Pharma May Acquire Dermatology Generics Business from Novartis 16
Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 17
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 18
Mallinckrodt May Sell Generic Drug Unit to Aurobindo Pharma 19
Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 20
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 21
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 22
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 23
Partnerships 25
Aurobindo Pharma Forms Joint Venture with Tergene Biotech 25
Celon Labs Forms Joint Venture with Aurobindo Pharma 26
Licensing Agreements 27
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 27
Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 29
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 30
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 31
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 32
Equity Offering 34
Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 34
Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 35
Asset Transactions 36
Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 36
Acquisition 37
Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 37
Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 38
Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 39
Aurobindo Pharma Acquires Natrol for USD132.5 Million 40
Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 41
Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 42
Aurobindo Pharma Ltd – Key Competitors 43
Aurobindo Pharma Ltd – Key Employees 44
Aurobindo Pharma Ltd – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 48
Recent Developments 49
Financial Announcements 49
May 28, 2018: Aurobindo Pharma Q4 FY17-18 and FY17-18 Financial Results 49
Nov 09, 2017: Aurobindo Pharma: Q2 FY17-18 Financial Results 51
Aug 09, 2017: Aurobindo Pharma: Consolidated Financial & Business Highlights – Q1FY18 53
Feb 09, 2017: Aurobindo Pharma Announces Q3 results & Limited Review Report for the Quarter ended December 31, 2016 54
Corporate Communications 55
Feb 09, 2017: Aurobindo Pharma Announces Change in Board of Directors 55
Legal and Regulatory 56
Mar 05, 2018: Aurobindo Pharma Issued Clarification on US FDA Observations 56
Mar 05, 2018: Aurobindo Announces Inspection of Unit 4 by US FDA 57
Mar 04, 2018: US inspectors cite serious quality issues at Aurobindo Pharma’s Unit 4 58
Apr 19, 2017: Aurobindo Pharma Provides Update on US FDA Inspection at Bachupally Manufacturing Facility 59
Product News 60
May 13, 2018: Aurobindo Pharma’s arm recalls 2 antibiotic injections from US 60
03/30/2017: Aurobindo Pharma receives USFDA Approval for Generic Epzicom tablets 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurobindo Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aurobindo Pharma to Acquire Generics Business of Apotex 13
Novartis May Sell US Generic Pill Business 14
Aurobindo Pharma May Acquire Dermatology Generics Business from Novartis 16
Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 17
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 18
Mallinckrodt May Sell Generic Drug Unit to Aurobindo Pharma 19
Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 20
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 21
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 22
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 23
Aurobindo Pharma Forms Joint Venture with Tergene Biotech 25
Celon Labs Forms Joint Venture with Aurobindo Pharma 26
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 27
Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 29
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 30
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 31
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 32
Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 34
Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 35
Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 36
Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 37
Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 38
Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 39
Aurobindo Pharma Acquires Natrol for USD132.5 Million 40
Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 41
Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 42
Aurobindo Pharma Ltd, Key Competitors 43
Aurobindo Pharma Ltd, Key Employees 44
Aurobindo Pharma Ltd, Other Locations 45
Aurobindo Pharma Ltd, Subsidiaries 45
Aurobindo Pharma Ltd, Joint Venture 48

List of Figures
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aurobindo Pharma Ltd (AUROPHARMA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mr.Sub:企業の戦略・SWOT・財務情報
    Mr.Sub - Strategy, SWOT and Corporate Finance Report Summary Mr.Sub - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • L’Oreal SA:企業のM&A・事業提携・投資動向
    L'Oreal SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's L'Oreal SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • East Japan Railway Co:企業の戦略・SWOT・財務分析
    East Japan Railway Co - Strategy, SWOT and Corporate Finance Report Summary East Japan Railway Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The Aerospace Corp:企業の戦略的SWOT分析
    The Aerospace Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Olympus Corp (7733):医療機器:M&Aディール及び事業提携情報
    Summary Olympus Corporation (Olympus) provides precision machinery and instruments. It develops, manufactures and markets equipment and devices for medical, healthcare, imaging, information, and other industrial markets. It offers medical systems such as endotherapy devices, medical endoscopes and t …
  • Biosensors International Group Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Biosensors International Group Ltd (Biosensors) is a medical devices company. It develops, manufactures and markets medical devices. The company products find application in Interventional cardiology and critical care procedures. The company classifies its products into four categories: Inte …
  • Continental AG:企業のM&A・事業提携・投資動向
    Continental AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Continental AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • CIMB Group Holdings Berhad:企業のM&A・事業提携・投資動向
    CIMB Group Holdings Berhad - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CIMB Group Holdings Berhad Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Amicus Therapeutics Inc (FOLD):製薬・医療:M&Aディール及び事業提携情報
    Summary Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company that focuses on the research, development and commercialization of small molecules drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. The company's lea …
  • Fulgent Genetics Inc (FLGT):企業の財務・戦略的SWOT分析
    Fulgent Genetics Inc (FLGT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Geron Corp (GERN):企業の財務・戦略的SWOT分析
    Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Hanesbrands Inc (HBI):企業の財務・戦略的SWOT分析
    Hanesbrands Inc (HBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PHX Energy Services Corp (PHX):企業の財務・戦略的SWOT分析
    Summary PHX Energy Services Corp (PHX Energy), formerly Phoenix Technology Income Fund is an energy service company that manufactures, designs, and engineers directional drilling technologies. The corporation’s equipment includes RADD, P-360 MWD, 360-CV MWD, E-360 MWD, 360 RWD, and performance motor …
  • AstraZeneca PLC:企業の戦略・SWOT・財務情報
    AstraZeneca PLC - Strategy, SWOT and Corporate Finance Report Summary AstraZeneca PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Omnicom Group Inc. (OMC):企業の財務・戦略的SWOT分析
    Omnicom Group Inc. (OMC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Allightsykes Pty Ltd
    Allightsykes Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Allightsykes Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • BayWa AG:戦略・SWOT・企業財務分析
    BayWa AG - Strategy, SWOT and Corporate Finance Report Summary BayWa AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • HealthCare Global Enterprises Ltd (HCG):企業の財務・戦略的SWOT分析
    Summary HealthCare Global Enterprises Ltd (HCG), formerly Curie Centre of Oncology Private Ltd is a healthcare service provider that provides medical care and treatment services. The company provides services such as clinical laboratory services, diagnosis services, medical oncology services, radiat …
  • Agilent Technologies Inc (A):企業の財務・戦略的SWOT分析
    Agilent Technologies Inc (A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Vivus Inc (VVUS):製薬・医療:M&Aディール及び事業提携情報
    Summary Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's marketed products include, Qsymia (phentermine and topiramate extended-release), indic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆